Laboratoires Pierre Fabre Explained

Pierre Fabre S.A.
Type:Private limited company
Industry:Pharmaceutical
Location:Paris, France[1]
Area Served:Worldwide
Num Employees:13,000 (2015) (Homepage)

Laboratoires Pierre Fabre is a French multinational pharmaceutical and cosmetics company. The company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international).[2] It is headquartered in the city of Castres, Midi-Pyrénées, France.[2]

Founded in 1962 by Pierre Fabre (1926-2013),[2] the company is present in over 130 countries. Laboratories Pierre Fabre had approximately 10,000 employees in 2012, 33% of whom are internationally based, while the remaining 6,700 employees were based in France.[2] The company's business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products. Pharmaceuticals and phytotherapy represent 47% of turnover, whereas cosmetics represent 53% (percentages of 2012 turnover).

Pierre Fabre is best known for its vinorelbine (Navelbine),[3] [4] an anticancer drug[5] of the vinca alkaloid class.[6] [7] [8] They also developed vinflunine,[9] a fluorinated vinca alkaloid derivative[10] [11] available in Australia for "advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen."[12]

Olivier Bohuon was Chief Executive from September 2010 to April 2011.[13]

The Pierre Fabre Foundation

The Pierre Fabre Foundation was recognized as a public utility in 1999,[14] and its mission is to enable communities from less advanced and emerging countries, as well as those plunged into severe crisis by political or economic upheaval and/or natural disaster, to access the quality and levels of everyday health care and the widely-used drugs defined by the WHO and other organisations as essential to human health.[15]

External links

Notes and References

  1. Web site: Company Overview of Pierre Fabre S.A. . https://web.archive.org/web/20090101135510/http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=895845 . dead . January 1, 2009 . December 9, 2014.
  2. News: Pierre Fabre, founder of pharmaceutical giant, dies . . . 2013-07-20 . 2013-08-17 . dead . https://web.archive.org/web/20130723023852/http://www.france24.com/en/20130720-pierre-fabre-founder-pharmaceutical-giant-dies . 2013-07-23 .
  3. Ngo. Quoc Anh. Roussi. Fanny. Cormier. Anthony. Thoret. Sylviane. Knossow. Marcel. Guénard. Daniel. Guéritte. Françoise. Synthesis and biological evaluation of Vinca alkaloids and phomopsin hybrids. Journal of Medicinal Chemistry. 2009. 52. 1. 134–142. 19072542. 10.1021/jm801064y.
  4. Molecules. 2012. 17. 5. 5893–5914. 10.3390/molecules17055893. Modifications on the basic skeletons of vinblastine and vincristine. Péter. Keglevich. Laszlo. Hazai. György. Kalaus. Csaba. Szántay. 22609781. 6268133. free.
  5. . 2011. 5. 131–144. 10.4137/CMO.S5074. 3117629. Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Bryan A.. Faller. Trailokya N.. Pandi. 21695100.
  6. van der Heijden. Robert. Jacobs. Denise I.. Snoeijer. Wim. Hallard. Didier. Verpoorte. Robert. 2004. The Catharanthus alkaloids: Pharmacognosy and biotechnology. Current Medicinal Chemistry. 11. 5. 607–628. 15032608. 10.2174/0929867043455846.
  7. Book: Raviña, Enrique. The evolution of drug discovery: From traditional medicines to modern drugs. 2011. John Wiley & Sons. 9783527326693. 157–159. Vinca alkaloids. https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA157.
  8. Book: Africa's gift to the world. 46–51. https://books.google.com/books?id=aXGmCwAAQBAJ&pg=PA46. Botanical Miracles: Chemistry of Plants That Changed the World. Raymond. Cooper. Jeffrey John. Deakin. CRC Press. 2016. 9781498704304.
  9. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status. Bristol-Myers Squibb. June 27, 2008. November 23, 2007. dead. May 28, 2008. https://web.archive.org/web/20080528000858/http://newsroom.bms.com/article_display.cfm?article_id=5223.
  10. Vinca Alkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives. Jacques. Fahy. Alain. Duflos. Jean-Paul. Ribet. Jean-Claude. Jacquesy. Christian. Berrier. Marie-Paule. Jouannetaud. Fabien. Zunino. J. Am. Chem. Soc.. 1997. 119. 36. 8576–8577. 10.1021/ja971864w.
  11. Kruczynski. Anna. Barret. Jean-Marc. Etiévant. Chantal. Colpaert. Francis. Fahy. Jacques. Hill. Bridget T.. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem. Pharmacol.. 55. 5. 635–648. 1998. 9515574. 10.1016/S0006-2952(97)00505-4.
  12. Web site: Vinflunine, solution concentration for I.V. infusion, 50 mg in 2 mL and 250 mg in 10 mL (as ditartrate), Javlor®  - November 2011. Pharmaceutical Benefits Scheme. March 16, 2012. June 22, 2017.
  13. Web site: Olivier BOHUON appointed Chief Executive Officer of Pierre Fabre SA. FierceBiotech. en. 2020-01-29.
  14. Web site: pbouchayer. History. 2021-09-19. Fondation Pierre Fabre. en-US.
  15. Web site: pbouchayer. DNA. 2021-09-19. Fondation Pierre Fabre. en-US.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Laboratoires Pierre Fabre".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.